Stockscreener 앱 받기
7.28
7.85%
-0.62
시간 외 거래:
7.96
0.68
+9.34%
전일 마감가:
$7.90
열려 있는:
$8.0999
하루 거래량:
34,891
Relative Volume:
0.85
시가총액:
$16.64M
수익:
순이익/손실:
$-28.00M
주가수익비율:
-0.3675
EPS:
-19.8108
순현금흐름:
$-10.93M
1주 성능:
-15.59%
1개월 성능:
-34.06%
6개월 성능:
+57.24%
1년 성능:
-81.43%
1일 변동 폭
$7.19
$8.0999
1주일 범위
$7.19
$9.05
52주 변동 폭
$3.015
$39.64
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
명칭
Akari Therapeutics Plc Adr
전화
(929) 274-7510
주소
401 EAST JACKSON STREET, TAMPA
Compare AKTX vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
7.28 | 16.64M | 0 | -28.00M | -10.93M | -19.81 |
VRTX
Vertex Pharmaceuticals Inc
|
498.50 | 126.35B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
226.30 | 90.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
778.36 | 80.14B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.30 | 51.46B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.52 | 41.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-20 | 업그레이드 | Maxim Group | Hold → Buy |
| 2026-04-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2026-01-05 | 개시 | Ladenburg Thalmann | Buy |
| 2025-07-18 | 개시 | Maxim Group | Buy |
| 2019-01-04 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | 업그레이드 | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | 재확인 | Chardan Capital Markets | Sell |
| 2016-07-11 | 개시 | Chardan Capital Markets | Sell |
모두보기
Akari Therapeutics Plc Adr 주식(AKTX)의 최신 뉴스
Akari Therapeutics plc ADSADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy - Sahm
Akari Therapeutics targets mid-2027 phase 1 trial for AKTX-101 - Investing.com
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation - Sahm
Akari Therapeutics Stock Price Forecast. Should You Buy AKTX? - StockInvest.us
Akari Therapeutics Plc Sponsored ADR Revenue Breakdown – LS:A4270Y - TradingView
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity - Sahm
Wondering what's happening in today's pre-market session? - ChartMill
Akari Therapeutics partners with Whitehawk on dual payload study By Investing.com - Investing.com South Africa
Akari Therapeutics partners with Whitehawk on dual payload study - Investing.com
Price to earnings forward of Akari Therapeutics Plc Sponsored ADR – TRADEGATE:CLA1 - TradingView
Form S-3/A Akari Therapeutics PLC For: 10 July By Investing.com - Investing.com South Africa
Form S-3/A Akari Therapeutics PLC For: 10 July By Investing.com - Investing.com Canada
Akari Therapeutics (NASDAQ: AKTX) files to register 5.99M ADSs from May 2026 private placement - Stock Titan
Akari Therapeutics (NASDAQ: AKTX) adds private‑placement warrants and purchase agreement exhibits - Stock Titan
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board - Finviz
Akari Therapeutics appoints Patricia LoRusso to advisory board - Investing.com
Akari Therapeutics appoints Patricia LoRusso to advisory board By Investing.com - Investing.com India
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board - Barchart.com
Akari Therapeutics (NASDAQ: AKTX) registers 5,999,999 ADSs, 80,000-shares each - Stock Titan
Akari Therapeutics completes $8.3m capital raise in Q2 - Investing.com
Akari Therapeutics completes $8.3m capital raise in Q2 By Investing.com - Investing.com India
AKTXAkari Therapeutics Plc ADR Options - Finviz
Form S-1/A Akari Therapeutics PLC For: 26 June By Investing.com - Investing.com South Africa
Form S-1/A Akari Therapeutics PLC For: 26 June By Investing.com - Investing.com Canada
White Lion resale of 2.5M Akari (NASDAQ: AKTX) ADSs under $25M equity deal - Stock Titan
AKTX Forecast — Price Target — Prediction for 2027 - TradingView
Akari Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AKTX) - TradingView
CLA1 Forecast — Price Target — Prediction for 2027 - TradingView
CLA1 Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Akari Therapeutics PLC For: 25 June By Investing.com - Investing.com India
Form 4 Akari Therapeutics PLC For: 25 June By Investing.com - Investing.com South Africa
Akari Therapeutics (AKTX) CEO granted stock options tied to ADS and financings - Stock Titan
Akari Therapeutics (AKTX) interim CFO granted new ADS awards - Stock Titan
A4270Y Forecast — Price Target — Prediction for 2027 - TradingView
AKTX Options Chain — NASDAQ:AKTX - TradingView
Akari Therapeutics PLC (FRA:CLA1) Valuation - GuruFocus
Akari Therapeutics Q1 2026 Earnings: EPS Misses Estimates but Stock Rises 5.7% on Pipeline HopeSurprise Factor Analysis - dars.gov.et
Large share issuance and governance votes ahead at Akari (NASDAQ: AKTX) 2026 AGM - Stock Titan
Diluted earnings per share (diluted EPS) of Akari Therapeutics Plc Sponsored ADR – TRADEGATE:CLA1 - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Sahm
symbol__ Stock Quote Price and Forecast - CNN
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Which stocks have an unusual volume on Thursday? - ChartMill
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Akari Therapeutics Plc Adr (AKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.10%
5.71%
자본화:
|
볼륨(24시간):